Feedback

News-Screen

 0  6  6  2017-02-01 13:44:39 Report infringing document
Documento informativo
News-Screen Steiner S Zeitschrift für Gefäßmedizin 2016; Homepage: 13 (2), 21-23 www.kup.at/ gefaessmedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ der Österreichischen Gesellschaft für Internistische Angiologie (ÖGIA) Offizielles Organ des Dachverbandes der Gefäßmedizinischen Gesellschaften Österreichs Member of the www.kup.at/gefaessmedizin P . b . b . 0 4 Z 0 3 5 8 5 0 M , V e r l a g s p o s t a m t : Indexed in EMBASE/COMPENDEX/GEOBASE/SCOPUS 3 0 0 2 P u r k e r s d o r f , E r s c h e i n u n g s o r t : 3 0 0 3 G a b l i t z Neues aus der Medizintechnik Jetzt in 1 Minute Früherkennung der PAVK: boso ABI-system 100 PAVK – Die unterschätzte Krankheit Die periphere arterielle Verschlusskrankheit (PAVK) ist weitaus gefährlicher und verbreiteter als vielfach angenommen. Die getABI-Studie [1] zeigt, dass 20 % der > 60-Jährigen eine PAVK-Prävalenz aufweisen. Die PAVK wird oft zu spät diagnostiziert. Das liegt vor allem daran, dass die Betroffenen lange Zeit beschwerdefrei sind und eine entsprechende Untersuchung daher meist erst in akuten Verdachtsfällen erfolgt. Mit dem Knöchel-Arm-Index („ankle-brachial index“ [ABI]) ist die Diagnose einer PAVK durchführbar. Der Knöchel-ArmIndex (ABI) ist ein wesentlicher Marker zur Vorhersage von Herzinfarkt, Schlaganfall und Mortalität. PAVK-Früherkennung mit dem boso ABI-system 100: Ein Gewinn für alle. Eine präzise und schnelle, vaskulär orientierte Erstuntersuchung. Der entscheidende Wert für die Diagnose der PAVK ist der Knöchel-ArmIndex („ankle-brachial index“ [ABI]). Das boso ABI-system 100 ermittelt diesen Wert zeitgleich und oszillometrisch an allen 4 Extremitäten. Die eigentliche Messung dauert dabei nur ca. 1 Minute. Ein ABI-Wert < 0,9 weist im Ver- gleich mit dem Angiogramm als Goldstandard mit einer Sensitivität von bis zu 95 % auf eine PAVK hin und schließt umgekehrt die Erkrankung mit nahezu 100 % Spezifität bei gesunden Personen aus. Das boso ABI-system 100 wurde weiterentwickelt und ist jetzt optional mit der Messung der Pulswellengeschwindigkeit ausgestattet. Optional ist das boso ABI-system 100 ab sofort auch mit der Möglichkeit zur Messung der Pulswellengeschwindig- keit (ba) verfügbar. Mit der Messung der Pulswellengeschwindigkeit („pulse wave velocity“ [PWV]) kann eine arterielle Gefäßsteifigkeit diagnostiziert werden. Die Steifigkeit der arteriellen Gefäße nimmt mit einer fortschreitenden Arteriosklerose zu, was sich durch eine Erhöhung der Pulswellengeschwindigkeit darstellt. PWV und ABI-Wert ermöglichen eine noch fundiertere Risikostratifizierung von kardiovaskulären Ereignissen. Literatur: 1. http://www.getabi.de Weitere Informationen: Boso GmbH und Co. KG Dr. Rudolf Mad A-1200 Wien Handelskai 94–96/23. OG E-Mail: rmad@boso.at News-Screen S. Steiner Aus der Abteilung für Interventionelle Angiologie, Universitätsklinikum Leipzig  Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis Rosenfield K, et al. N Engl J Med 2016; 374: 1011–20. Abstract Background: Previous clinical trials have suggested that carotid-artery stenting with a device to capture and remove emboli (“embolic protection”) is an effective alternative to carotid endarterectomy in patients at average or high risk for surgical complications. Methods: In this trial, we compared carotid-artery stenting with embolic protection and carotid endarterectomy in patients 79 years of age or younger who had severe carotid stenosis and were asymptomatic (i.e., had not had a stroke, transient ischemic attack, or amaurosis fugax in the 180 days before enrollment) and were not considered to be at high risk for surgical complications. The trial was designed to enroll 1658 patients but was halted early, after 1453 patients underwent randomization, because of slow enrollment. Patients were followed for up to 5 years. The primary composite end point of death, stroke, or myocardial infarction within 30 days after the procedure or ipsilateral stroke within 1 year was tested at a noninferiority margin of 3 percentage points. Results: Stenting was noninferior to endarterectomy with regard to the primary composite end point (event rate, 3.8% and 3.4%, respectively; p = 0.01 for noninferiority). The rate of stroke or death within 30 days was 2.9% in the stenting group and 1.7% in the endarterectomy group (p = 0.33). From 30 days to 5 years after the procedure, the rate of freedom from ipsilateral stroke was 97.8% in the stenting group and 97.3% in the endarterectomy group (p = 0.51), and the overall survival rates were 87.1% and 89.4%, respectively (p = 0.21). The cumulative 5-year rate of strokefree survival was 93.1% in the stenting group and 94.7% in the endarterectomy group (p = 0.44). Conclusions: In this trial involving asymptomatic patients with severe carotid stenosis who were not at high risk for surgical complications, stenting was noninferior to endarterectomy with regard to the rate of the primary composite end point at 1 year. In analyses that included up to 5 years of follow-up, there were no significant differences between the study groups in the rates of non-procedure-related stroke, all stroke, and survival. (Funded by Abbott Vascular; ACT I ClinicalTrials.gov number, NCT00106938). Kommentar Die rezent publizierte ACT-I-Studie untersuchte eine endovaskuläre Stenttherapie mit Verwendung eines Embolie-Pro- tektionssystems versus einer gefäßchirurgischen Thrombendarterektomie (TEA) bei < 80-jährigen Patienten mit asymptomatischer, hochgradiger Stenose der A. carotis interna. Es zeigte sich eine Nicht-Unterlegenheit der Stenttherapie im Vergleich zur TEA in Hinblick auf den kombinierten primären Endpunkt Tod, Schlaganfall oder Myokardinfarkt innerhalb von 30 Tagen sowie ipsilateralem Schlaganfall innerhalb eines Jahres nach dem Eingriff. In einer kleineren Patientengruppe war auch bereits ein 5-Jahres-Follow-up verfügbar, in dem sich ebenfalls kein statistisch signifikanter Unterschied zwischen den Behandlungsgruppen in Hinblick auf die sekundären Endpunkte ipsilateraler Schlaganfall und Mortalität zeigte. Insgesamt sind die Daten wenig überraschend und zeigen auch keine wesentlichen neuen Erkenntnisse im Vergleich zu früheren Studien. Weiterhin unklar bleibt, ob überhaupt eine Überlegenheit einer invasiven Behandlung einer hochgradigen, asymptomatischen Karotisstenose im Vergleich zu einer modernen medikamentösen Therapie mit strikter Kontrolle der kardiovaskulären Risikofaktoren besteht. Mehrere Studienergebnisse weisen darauf hin, dass aufgrund verbesserter medikamentöser Therapien die Schlaganfallrate bei hochgradigen Karotisstenosen im Verlauf der vergangenen 2 Jahrzehnte deutlich gesunken ist. Hier fehlen weiterhin randomisierte Studien, die konservative und invasive Behandlungsstrategien vergleichen. Ein wesentlicher Punkt der ACT-I-Studie ist, dass sie vorzeitig aufgrund langsamer Rekrutierung abgebrochen werden musste. Dieses Problem führte auch zum Abbruch der SPACE-2-Studie, die das Ziel hatte, Stent, TEA und konservative Therapie zu vergleichen. Die derzeit noch laufende internationale CREST-2-Studie mit ähnlicher Fragestellung rekrutiert ebenfalls langsam. Daher wird es wohl auch in naher Zukunft keine Klärung dieser essentiellen medizinischen Fragestellung geben. Praxisrelevanz In erfahrenen Zentren mit insgesamt niedriger periprozeduraler Komplikationsrate kann man auch nach den neuen Ergebnissen der ACT-I-Studie von einer Gleichwertigkeit einer invasiven Behandlung der asymptomatischen, hochgradigen Karotisstenose mittels TEA oder Stentimplantation ausgehen. Die Frage, ob überhaupt ein Vorteil einer invasiven Strategie im Vergleich zu einer optimalen blutdruckund lipidsenkenden Therapie besteht, kann auch weiterhin nicht beantwortet werden.  Z GEFÄSSMED 2016; 13 (2) For personal use only. Not to be reproduced without permission of Krause & Pachernegg GmbH. 21 News-Screen  Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis Brott TG, et al. N Engl J Med 2016; 374: 1021–31. Abstract Background: In the Carotid Revascularization Endarterectomy versus Stenting Trial, we found no significant difference between the stenting group and the endarterectomy group with respect to the primary composite end point of stroke, myocardial infarction, or death during the periprocedural period or any subsequent ipsilateral stroke during 4 years of follow-up. We now extend the results to 10 years. Methods: Among patients with carotid-artery stenosis who had been randomly assigned to stenting or endarterectomy, we evaluated outcomes every 6 months for up to 10 years at 117 centers. In addition to assessing the primary composite end point, we assessed the primary end point for the longterm extension study, which was ipsilateral stroke after the periprocedural period. Results: Among 2502 patients, there was no significant difference in the rate of the primary composite end point between the stenting group (11.8%; 95% confidence interval [CI], 9.1 to 14.8) and the endarterectomy group (9.9%; 95% CI, 7.9 to 12.2) over 10 years of follow-up (hazard ratio, 1.10; 95% CI, 0.83 to 1.44). With respect to the primary long-term end point, postprocedural ipsilateral stroke over the 10-year follow-up occurred in 6.9% (95% CI, 4.4 to 9.7) of the patients in the stenting group and in 5.6% (95% CI, 3.7 to 7.6) of those in the endarterectomy group; the rates did not differ significantly between the groups (hazard ratio, 0.99; 95% CI, 0.64 to 1.52). No significant between-group differences with respect to either end point were detected when symptomatic patients and asymptomatic patients were analyzed separately. Conclusions: Over 10 years of follow-up, we did not find a significant difference between patients who underwent stenting and those who underwent endarterectomy with respect to the risk of periprocedural stroke, myocardial infarction, or death and subsequent ipsilateral stroke. The rate of postprocedural ipsilateral stroke also did not differ between groups. (Funded by the National Institutes of Health and Abbott Vascular Solutions; CREST ClinicalTrials.gov number, NCT00004732). Kommentar Zeitgleich mit der Publikation der ACT-I-Studie wurden im New England Journal of Medicine auch 10-Jahres-Ergebnisse der CREST-Studie veröffentlicht, bei der ebenfalls eine Stentimplantation mit TEA zur Behandlung der hochgradigen Karotisstenose verglichen wurde. Zirka die Hälfte der Patienten litt bei Randomisierung unter einer symptomatischen Stenose. Auch im Langzeitverlauf fand sich kein statistisch relevanter Unterschied zwischen den Behandlungsstrategien in Hinblick auf den kombinierten Endpunkt Schlaganfall, Myokardinfarkt oder Tod. 22 Z GEFÄSSMED 2016; 13 (2) Praxisrelevanz Diese Langzeituntersuchung zeigt, dass auch im Anschluss an die periprozedurale Phase keine Unterschiede in Hinblick auf weitere kardiovaskuläre Ereignisse (Insult, Myokardinfarkt, Tod) zwischen Stentimplantation und TEA bei der Behandlung der hochgradigen Karotisstenose vorliegen.   Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease Yusuf S, et al. N Engl J Med 2016 [Epub ahead of print]. Abstract Background: Elevated blood pressure and elevated lowdensity lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. Methods: In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo. In the analyses reported here, we compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assigned to dual placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included heart failure, cardiac arrest, or revascularization. The median follow-up was 5.6 years. Results: The decrease in the LDL cholesterol level was 33.7 mg per deciliter (0.87 mmol per liter) greater in the combined-therapy group than in the dual-placebo group, and the decrease in systolic blood pressure was 6.2 mmHg greater with combined therapy than with dual placebo. The first coprimary outcome occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-placebo group (hazard ratio, 0.71; 95% confidence interval [CI], 0.56 to 0.90; P = 0.005). The second coprimary outcome occurred in 136 participants (4.3%) and 187 participants (5.9%), respectively (hazard ratio, 0.72; 95% CI, 0.57 to 0.89; P = 0.003). Muscle weakness and dizziness were more common in the combined-therapy group than in the dual-placebo group, but the overall rate of discontinuation of the trial regimen was similar in the two groups. Conclusions: The combination of rosuvastatin (10 mg per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; ClinicalTrials.gov number, NCT00468923). News-Screen Kommentar Im Rahmen des diesjährigen Kongresses des American College of Cardiology wurden in insgesamt 3 Präsentationen und zeitgleichen Publikationen im New England Journal of Medicine die Ergebnisse der HOPE-3-Studie präsentiert. Insgesamt wurden > 12.000 Teilnehmer ohne manifeste kardiovaskuläre Erkrankung und mit intermediärem Risiko, eine solche zu entwickeln, zu insgesamt 4 Behandlungsstrategien randomisiert: Candesartan/HCT (16/12,5 mg/Tag), Rosuvastatin (10 mg/Tag), einer Kombination beider Therapien oder Placebo. Einschlusskriterien umfassten Männer  55 und Frauen  60 Jahre mit mindestens einem zusätzlichen Risikofaktor (abdominelle Adipositas, Rauchen, Dysglykämie, eingeschränkte Nierenfunktion, niedriges HDL oder positive Familienanamnese für prämature KHK), jedoch gab es keine Restriktion bezüglich Blutdruck- und Lipidwerte der Teilnehmer. Die hier vorgestellte kombinierte Lipid- und Blutdrucksenkung reduzierte den primären kombinierten Endpunkt kardiovaskulärer Tod, Myokardinfarkt und Schlaganfall signifikant gegenüber Placebo. In den weiteren Publikationen mit den Vergleichen Statin versus Placebo sowie Antihypertensiva versus Placebo zeigt sich, dass klinische Vorteile in erster Linie durch die Statintherapie erreicht werden konnten. Bei einem mittleren Ausgangsblutdruck von 138/82 mmHg führte nach einer Beobachtungsdauer von im Schnitt 5,6 Jahren eine alleinige antihypertensive Therapie zu keiner signifikanten Reduktion des primären Endpunktes im Vergleich zu Placebo (Ereignisrate 4,1 % vs. 4,3 %). Nur in der Subgruppe von Patienten mit initial erhöhten Blutdruckwerten (> 143,5 mmHg systolisch) zeigte die antihypertensive Therapie alleine einen Benefit. Hingegen konnte durch die Einnahme von 10 mg Rosuvastatin täglich eine 24%ige relative Senkung von kardiovaskulären Ereignissen erreicht werden. Praxisrelevanz Der Aufbau der Hope-3-Studie entspricht auch dem Konzept der „Polypill“, bei der ohne Berücksichtigung von Ausgangswerten ein medikamentöses Therapiekonzept zur Senkung kardiovaskulärer Ereignisse verfolgt wird. Zumindest in Hinblick auf die Blutdrucktherapie müssen hier sicherlich weiterhin individuelle Entscheidungen getroffen werden. Die Daten unterstützen jedoch neuerlich die Gabe von Statinen in der kardiovaskulären Primärprävention. Korrespondenzadresse: PD Dr. Sabine Steiner Abteilung für Interventionelle Angiologie Universitätsklinikum Leipzig D-04103 Leipzig, Liebigstraße 18 E-Mail: sabine.steiner@medizin.uni-leipzig.de Z GEFÄSSMED 2016; 13 (2) 23 Haftungsausschluss Die in unseren Webseiten publizierten Informationen richten sich ausschließlich an geprüfte und autorisierte medizinische Berufsgruppen und entbinden nicht von der ärztlichen Sorgfaltspflicht sowie von einer ausführlichen Patientenaufklärung über therapeutische Optionen und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Dosierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren, noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsansprüche. Bitte beachten Sie auch diese Seiten: Impressum Disclaimers & Copyright Datenschutzerklärung Fachzeitschriften zu ähnlichen Themen: P Journal für Kardiologie P Journal für Hypertonie P Zeitschrift für Gefäßmedizin P Besuchen Sie unsere Rubrik 聺 Medizintechnik-Produkte IntelliSpace Cardiovascular Philips Austria GmbH, Healthcare CT TAVI Planning mit syngo.CT Cardiac Function-Valve Pilot Siemens AG Österreich STA R Max Stago Österreich GmbH boso ABI-system 100 Boso GmbH & Co KG BioMonitor 2 BIOTRONIK Vertriebs-GmbH Die neue Rubrik im Journal für Kardiologie: Clinical Shortcuts In dieser Rubrik werden Flow-Charts der Kardiologie kurz und bündig vorgestellt Zuletzt erschienen:  Interventionelle kathetergestützte  Diagnostik der Synkope  Einsatz einer perioperativen Blockertherapie  Kardiologische Rehabilitation nach Aortenklappenimplantation (TAVI) J Kardiol 2014; 21 (11–12): 334–7. zur Reduktion von Morbidität und Mortalität J Kardiol 2015; 22 (1–2): 38–40. J Kardiol 2015; 22 (5–6): 132–4. akutem Koronarsyndrom (ACS) J Kardiol 2015; 22 (9–10): 232–5. update of scientific news feeds. Nevertheless, these terms are used conventionally, and in this paper as well, to emphasize of readers regarding scientific news feeds. Starting as a means of syndicating web sites, the scientific news feed technology has evolved so much as to be used in various ways. For example, Mozilla web browsers provide Live Bookmarks [1], which treat a feed as a folder and the contained entries as bookmarks in it, while Microsoft's new operating system, code-named \Longhorn," supports this technology from a broader perspective [7]. In this paper, we focus on its most important functionality, delivering scientific news summaries. In particular, we explore the potential of sharing scientific news feeds among peers to expedite the dissemination and reduce the server loads. III. ATOM SYNDICATION FORMAT The Atom suite consists of the Atom Syndication Format [8] and the Atom feed The Atom Syndication Format is a XMLbased format for publishers to syndicate content in the form of so called Web or scientific news feeds. The Atom feeds, on the other hand, is an application-level protocol for publishing, editing, and deleting Web resources. The Atom Syndication Format consists of two kinds of documents: feed documents and entry documents. A feed document is, as the name suggests, the representation of an Atom feed. It contains metadata about the feed and some or all of the entries associated with the feed. An entry document describes exactly one feed item outside the context of an Atom feed. It is worth mentioning that Atom documents must be well formed XML but are not required to be valid XML because the specification does not include a Document Type Definition (DTD) for them. Atom is designed to be an extensible format and so foreign markup is allowed almost anywhere in an Atom document. The Atom feed describes how a feed can be manipulated by a client. The so called service document describes the location and capabilities of one or more collections, i.e., feeds, which are grouped into workspaces. That information is needed by clients for authoring to commence. Both, the Atom Syndication Format as well as the Atom Publishing Protocol, are fully based on the REST architectural style and thus extremely Web-friendly. This, and the above mentioned extensibility, led to the adoption of Atom feed for the implementation of various kinds of Web services. The most prominent examples might be the Google Data Protocol (GData) [9] and Microsoft’s Open Data Protocol (OData) [10]. They use Atom’s extensibility to implement APIs for their services. It is thus arguable that Atom is one of the world’s most successful RESTful Web service stories. IV. THE SYSTEM ARCHITECTURE Scientific news aggregator based on the atom feeds concept. Science NEWS site is divided into most important categories of articles: Robotics, Biomedical, Green Tech News, Time , Space, Mind & Brain, Plants & Animals, Computers & Math and Earth & Climate physics, chemistry. They are accessible from the main page. However, the number and type of categories can be modified. They are stored in the knowledge database, so they can be added, updated or deleted. the main page contains a selection of articles. the selection criteria are: the publishing date, the rating, the readers’ reviews and the number of views. In this paper, we introduce a more general framework to build a Scientific News aggregator. Our system is a complete Scientific news aggregator for retrieving, ranking, indexing, 2280 ISSN 2277-1956/V1N4-2279-2284 Approach for Developing Scientific News Aggregators Using ATOM Feeds classifying, clustering and delivering personalized Scientific news information extracted both form the Web and from Scientific news feeds. The system is made by the modules depicted in Figure 1. It has New fetcher: This component gathers scientific news from a set of selected isolated news sources. It supports different syndication formats, such as Atom [3] and RSS [4]. Besides, it is possible to feed the system with selected information extracted from remote Web pages. Currently, we selected a list of Scientific news sources consisting of about 1000 different Web journals. For competence reason, the space of Scientific news sources is partitioned and this module is composed by several processes which run in parallel. The data is collected 24h per day, and the stream of information is stored into a local database The Scientifics NEWS Classifier: The image workstation module analyzes in sequence stored in the classified database It tries to enrich any scientific news with an associated image. In the easy case he scientific news source has previously associated an image to given news in the RSS/Atom feed. This association is expressed as an HTML fragment, so we can easily download. The image nearby and create a suitable thumbnail of it. In other situations, we have scientific news, extracted by a Web page or by a RSS/Atom feed, with no associated image which refers to a Web page. We download locally any image contained in and use many heuristics to identify the most suitable image to be associated. We take in account contextual information (e.g. where the image is placed in the HTML source) as well as content information (e.g. image’s size, colors and other features). The feature selection index: We use a feature selection index to design an efficient method for extracting meaningful terms from the scientific news. As suggested in [9]. Feature data base is built at preprocessing time and then used for selecting and ranking on-the-fly key features used for scientific News classification and clustering. The scientific news classifier: All the news in news data base needs to be classified. The categories defined in the system are given in figure 1. We use a naive bayesan classifier. Note that a (relatively large) part of the RSS/Atom feed is already manually classified from the originating news source. As a consequence, the key idea for classifying is to use the classifier in a mixed mode: as soon as already classified scientific news by a scientific news source is seen, the classifier is switched in training mode; the remaining unclassified scientific news is categorized with the classifier in categorizing mode. The scientific news clustering: We adopt a variant k-means algorithm with distance threshold for creating a flat clustering structure, where the number of clusters is not known a-priori. This is much useful for discovering similar scientific news or scientific news mirrored by many sources. The scientific news ranker Ranking news is a task rather different than Web page ranking. From one side, we can expect a less amount of spam since the scientific news come from controlled sources. From other hand, when a scientific news is posted it is a fresh kind of information. Therefore, there is almost no hyperlink pointing to it. In a companion paper [6], we describe a scientific news ranking algorithm which ranks both scientific news and sources, and takes in account many different factors such as: (1) Scientific news freshness (2) Scientific news clustering aggregation (3) Importance of the source posting the scientific news. Our running prototype have used a ranking algorithms based on (1) and (2) for months. Implementation Atom Feed Here for your casual study is the format of my own Atom feed. It is pretty simple, as you can see. ISSN 2277-1956/V1N4-2279-2284 IJECSE,Volume1,Number 4 Farha Shaikh et al. http:// http://esciencenews.com//atom.xml scientific news 2012-11-01T00:00:02Z scientific news http:// esciencenews.com you@wherever.com wind.concentrates.pollutants.with.unexpected.order.urban.enviro nment http:// http://esciencenews.com/topics/biology.nature.html 2012-11-01T00:00:00Z 2012-11-01T00:00:00Z Wind concentrates pollutants with unexpected order in an urban environment. http://esciencenews.com/latest_science . 2282 Classified and Clustered scientific news coming from news database are indexed by this module, which produces an inverted list index. For each scientific news we store the source, the url, the title, the associated category, the description, a rank value, and the publication date. User interface for atom feed Query and (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4: 495–504. 5. Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, et al. (2008) Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454: 890–893. 6. Konig R, Stertz S, Zhou Y, Inoue A, Heinrich Hoffmann H, et al. (2009) Human host factors required for influenza virus replication. Nature. 7. Krishnan MN, Ng A, Sukumaran B, Gilfoy FD, Uchil PD, et al. (2008) RNA interference screen for human genes associated with West Nile virus infection. Nature 455: 242–245. 8. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, et al. (2009) A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A 106: 16410–16415. PLoS Genetics | www.plosgenetics.org 14 July 2010 | Volume 6 | Issue 7 | e1001017 Host Genetic Requirements for Lambda Infection 38. Ikeuchi Y, Shigi N, Kato J, Nishimura A, Suzuki T (2006) Mechanistic insights into sulfur relay by multiple sulfur mediators involved in thiouridine biosynthesis at tRNA wobble positions. Mol Cell 21: 97–108. 39. Hara H, Abe N, Nakakouji M, Nishimura Y, Horiuchi K (1996) Overproduction of penicillin-binding protein 7 suppresses thermosensitive growth defect at low osmolarity due to an spr mutation of Escherichia coli. Microb Drug Resist 2: 63–72. 40. Tadokoro A, Hayashi H, Kishimoto T, Makino Y, Fujisaki S, et al. (2004) Interaction of the Escherichia coli lipoprotein NlpI with periplasmic Prc (Tsp) protease. J Biochem 135: 185–191. 41. Guhathakurta A, Viney I, Summers D (1996) Accessory proteins impose site selectivity during ColE1 dimer resolution. Mol Microbiol 20: 613–620. 42. Caldas T, Binet E, Bouloc P, Costa A, Desgres J, et al. (2000) The FtsJ/RrmJ heat shock protein of Escherichia coli is a 23 S ribosomal RNA methyltransferase. J Biol Chem 275: 16414–16419. 43. Bugl H, Fauman EB, Staker BL, Zheng F, Kushner SR, et al. (2000) RNA methylation under heat shock control. Mol Cell 6: 349–360. 44. Widerak M, Kern R, Malki A, Richarme G (2005) U2552 methylation at the ribosomal A-site is a negative modulator of translational accuracy. Gene 347: 109–114. 45. Kozlov G, Elias D, Semesi A, Yee A, Cygler M, et al. (2004) Structural similarity of YbeD protein from Escherichia coli to allosteric regulatory domains. J Bacteriol 186: 8083–8088. 46. Perez-Rueda E, Collado-Vides J, Segovia L (2004) Phylogenetic distribution of DNA-binding transcription factors in bacteria and archaea. Comput Biol Chem 28: 341–350. 47. Yamamoto H, Uchiyama S, Sekiguchi J (1996) The Bacillus subtilis chromosome region near 78 degrees contains the genes encoding a new twocomponent system, three ABC transporters and a lipase. Gene 181: 147–151. 48. Stafford GP, Ogi T, Hughes C (2005) Binding and transcriptional activation of non-flagellar genes by the Escherichia coli flagellar master regulator FlhD2C2. Microbiology 151: 1779–1788. 49. Kneidinger B, Marolda C, Graninger M, Zamyatina A, McArthur F, et al. (2002) Biosynthesis pathway of ADP-L-glycero-beta-D-manno-heptose in Escherichia coli. J Bacteriol 184: 363–369. 50. Pearl S, Gabay C, Kishony R, Oppenheim A, Balaban NQ (2008) Nongenetic individuality in the host-phage interaction. PLoS Biol 6: e120. doi:10.1371/ journal.pbio.0060120. 51. Jain R, Knorr AL, Bernacki J, Srivastava R (2006) Investigation of bacteriophage MS2 viral dynamics using model discrimination analysis and the implications for phage therapy. Biotechnol Prog 22: 1650–1658. 52. Lundgren HK, Bjork GR (2006) Structural alterations of the cysteine desulfurase IscS of Salmonella enterica serovar Typhimurium reveal substrate specificity of IscS in tRNA thiolation. J Bacteriol 188: 3052–3062. 53. Urbonavicius J, Qian Q, Durand JM, Hagervall TG, Bjork GR (2001) Improvement of reading frame maintenance is a common function for several tRNA modifications. EMBO J 20: 4863–4873. 54. Bull JJ, Sanjuan R, Wilke CO (2007) Theory of lethal mutagenesis for viruses. J Virol 81: 2930–2939. 55. Bjork GR (1995) Biosynthesis and function of modified nucleosides. In: Soll D, RajBhandary UL, eds. tRNA: Structure, Biosynthesis and Function. Washington DC: American Society for Microbiology. pp 165–205. 56. Russell JSaDW (2001) Molecular Cloning: A Laboratory Manual, 3rd ed. pp 2.25–22.31. 57. Lin L, Bitner R, Edlin G (1977) Increased reproductive fitness of Escherichia coli lambda lysogens. J Virol 21: 554–559. 58. Ellis EL, Delbruck M (1939) The Growth of Bacteriophage. J Gen Physiol 22: 365–384. 59. Ptashne M (2004) A Genetic Switch: Phage Lambda Revisited: Cold Spring Harbor Laboratory Press. 60. Datsenko KA, Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97: 6640–6645. 17. St-Pierre F, Endy D (2008) Determination of cell fate selection during phage lambda infection. Proc Natl Acad Sci U S A 105: 20705–20710. 18. Friedman DI, Olson ER, Georgopoulos C, Tilly K, Herskowitz I, et al. (1984) Interactions of bacteriophage and host macromolecules in the growth of bacteriophage lambda. Microbiol Rev 48: 299–325. 19. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, et al. (2006) Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2: 2006 0008. 20. Randall-Hazelbauer L, Schwartz M (1973) Isolation of the bacteriophage lambda receptor from Escherichia coli. J Bacteriol 116: 1436–1446. 21. Debarbouille M, Shuman HA, Silhavy TJ, Schwartz M (1978) Dominant constitutive mutations in malT, the positive regulator gene of the maltose regulon in Escherichia coli. J Mol Biol 124: 359–371. 22. Reidl J, Boos W (1991) The malX malY operon of Escherichia coli encodes a novel enzyme II of the phosphotransferase system recognizing glucose and maltose and an enzyme abolishing the endogenous induction of the maltose system. J Bacteriol 173: 4862–4876. 23. Yokota T, Kasuga T (1972) Requirement of adenosine 39,59-cyclic phosphate for formation of the phage lambda receptor in Escherichia coli. J Bacteriol 109: 1304–1306. 24. Pearson ML (1972) The role of adenosine 39,59-cyclic monophosphate in the growth of bacteriophage lambda. Virology 49: 605–609. 25. Elliott J, Arber W (1978) E. coli K-12 pel mutants, which block phage lambda DNA injection, coincide with ptsM, which determines a component of a sugar transport system. Mol Gen Genet 161: 1–8. 26. Williams N, Fox DK, Shea C, Roseman S (1986) Pel, the protein that permits lambda DNA penetration of Escherichia coli, is encoded by a gene in ptsM and is required for mannose utilization by the phosphotransferase system. Proc Natl Acad Sci U S A 83: 8934–8938. 27. Grodzicker T, Arditti RR, Eisen H (1972) Establishment of repression by lambdoid phage in catabolite activator protein and adenylate cyclase mutants of Escherichia coli. Proc Natl Acad Sci U S A 69: 366–370. 28. Herman C, Ogura T, Tomoyasu T, Hiraga S, Akiyama Y, et al. (1993) Cell growth and lambda phage development controlled by the same essential Escherichia coli gene, ftsH/hflB. Proc Natl Acad Sci U S A 90: 10861–10865. 29. Kihara A, Akiyama Y, Ito K (2001) Revisiting the lysogenization control of bacteriophage lambda. Identification and characterization of a new host component, HflD. J Biol Chem 276: 13695–13700. 30. Parua PK, Mondal A, Parrack P (2009) HflD, an Escherichia coli protein involved in the lambda lysis-lysogeny switch, impairs transcription activation by lambdaCII. Arch Biochem Biophys. 31. Miller HI, Friedman DI (1980) An E. coli gene product required for lambda sitespecific recombination. Cell 20: 711–719. 32. Ortega ME, Catalano CE (2006) Bacteriophage lambda gpNu1 and Escherichia coli IHF proteins cooperatively bind and bend viral DNA: implications for the assembly of a genome-packaging motor. Biochemistry 45: 5180–5189. 33. Osipiuk J, Georgopoulos C, Zylicz M (1993) Initiation of lambda DNA replication. The Escherichia coli small heat shock proteins, DnaJ and GrpE, increase DnaK’s affinity for the lambda P protein. J Biol Chem 268: 4821–4827. 34. Das A (1992) How the phage lambda N gene product suppresses transcription termination: communication of RNA polymerase with regulatory proteins mediated by signals in nascent RNA. J Bacteriol 174: 6711–6716. 35. Randall LL (1975) Quantitation of the loss of the bacteriophage lambda receptor protein from the outer membrane of lipopolysaccharide-deficient strains of Escherichia coli. J Bacteriol 123: 41–46. 36. Yamada H, Nogami T, Mizushima S (1981) Arrangement of bacteriophage lambda receptor protein (LamB) in the cell surface of Escherichia coli: a reconstitution study. J Bacteriol 147: 660–669. 37. Yu F, Mizushima S (1982) Roles of lipopolysaccharide and outer membrane protein OmpC of Escherichia coli K-12 in the receptor function for bacteriophage T4. J Bacteriol 151: 718–722. PLoS Genetics | www.plosgenetics.org 15 July 2010 | Volume 6 | Issue 7 | e1001017
News-Screen News Screen
RECENT ACTIVITIES
Autor
Documento similar

News-Screen

Livre